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BACKGROUND: Celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, also has anti-proliferative properties and
pro-apoptotic effects on different in vivo and in vitro models, two actions that may be efficacious in therapy for endo-
metriosis. We evaluated the effects of celecoxib on apoptosis and proliferation, and vascular endothelial growth factor
(VEGF) production and COX-2 expression and activity in endometrial epithelial cells (EECs). METHODS AND
RESULTS: Thirty-two endometriosis and 13 control women were included in the study. EECs from eutopic endome-
trium and control biopsies were cultured with different doses of celecoxib. Celecoxib at 50, 75 and 100 mM (versus
vehicle control) inhibited EEC proliferation in cultures from controls (P < 0.05, P < 0.01 and P < 0.01, respectively)
and patients with endometriosis (P < 0.05, P < 0.01 and P < 0.01), as assessed by 3H-thymidine uptake. Celecoxib at
50, 75 and 100 mM induced apoptosis in EEC from controls (P < 0.05, P < 0.001 and P < 0.001) and patients with endo-
metriosis (P < 0.001, P < 0.001 and P < 0.01), as revealed by the Acridine Orange–Ethidium Bromide technique.
Western blot analysis showed that celecoxib was effective at increasing COX-2 protein at 100 mM in EEC from endo-
metriosis patients (P < 0.05). In EEC from endometriosis patients, celecoxib at 25, 50 and 100 mM was also effective in
reducing COX-2 activity, reflected in the reduction of prostaglandin E2 (PGE2) synthesis (P < 0.001), and VEGF
secretion (P < 0.001; P < 0.05 and P < 0.001), assessed by enzyme-linked immunosorbent assay. Exogenous PGE2
did not reverse celecoxib-induced growth inhibition. CONCLUSIONS: This study suggests a direct effect of celecoxib
on reduction of endometrial growth and supports further research on selective COX-2 inhibition as a novel thera-
peutic modality in endometriosis.
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Introduction
Endometriosis is one of the most common benign gynaecological
diseases in women of reproductive age and is defined as the pre-
sence and proliferation of endometrial glands and stroma outside
the uterine cavity. This disease is estrogen-dependent and its
medical treatment is principally aimed at down-regulating the
ovarian estrogen production by the application of GnRH ago-
nists, progestins, androgenic agents or oral contraceptives
either in a continuous or cyclic fashion. Unfortunately, these
treatments are often associated with side effects and high recur-
rence rates (Valle and Sciarra, 2003; Mihalyi et al., 2006). There
is a real need for more effective approaches to the prevention and
treatment of endometriosis. Cyclooxygenase (COX)-2 inhibitors
show great promise in this respect (Ebert et al., 2005).
COX-1 and COX-2 are isoenzymes that execute the synthesis
of prostaglandins (PGs). While COX-1 is constitutively
expressed in tissue, COX-2 is inducible and up-regulated in
pathways of pain and inflammation (Vane et al., 1994; Ebert
et al., 2005). Non-steroidal anti-inflammatory drugs (NSAIDs)
are the most widely used therapeutic agents in the treatment of
pain and inflammation. Unlike regular NSAIDs, COX-2 selec-
tive inhibitors do not inhibit COX-1 and thus show promise as
drugs that spare the gastrointestinal system. Celecoxib is a
potent COX-2 inhibitor being developed for the treatment of
rheumatoid arthritis and osteoarthritis (Chun and Surh, 2004).
Consistent data suggest that COX-2 inhibitors can reduce
cancer risk in patients, can prevent tumorigenesis and suppress
established tumour growth in animals (Bundred and Barnes,
2005). In addition, COX-2-specific inhibitors have the ability
to block cell growth and induce apoptosis and cell cycle
arrest in various tumour cell lines (Kundu et al., 2002; Basu
et al., 2005). Also, it has been shown that COX-2 inhibitors
such as celecoxib are potent inhibitors of angiogenesis both
in vitro and in vivo (Gately and Li, 2004; Basu et al., 2005).
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COX-2 overexpression was detected in eutopic and ectopic
endometrium from patients with endometriosis (Ota et al.,
2001; Matsuzaki et al., 2004b). Furthermore, large amounts
of PGs have been found in peritoneal fluid from endometriosis
patients and endometriotic lesions (De Leon et al., 1986). It has
been shown that PGE2 overproduction leads to excessive estra-
diol formation and that estradiol and cytokines (interleukin-1b
and tumour necrosis factor-a), which are increased in endome-
triosis, induce COX-2 (Attar and Bulun, 2006). In addition, the
COX-2/vascular endothelial growth factor (VEGF) association
has been shown in human samples of non-small cell lung cancer
(Gately and Li, 2004). PGE2 increases VEGF production
(Gately and Li, 2004) and then VEGF stimulates COX-2
expression in endothelial cells (Tamura et al., 2006). This
pathway establishes a positive feedback loop in favour of
high concentrations of estrogen, PGE2 and VEGF in endome-
triosis (Bulun et al., 2002). Based on these data, we can specu-
late that inhibition of COX-2 would be a promising therapy
toward controlling the growth of the endometriotic lesion.
In endometriosis research, recent animal studies demon-
strated that treatment with COX-2 inhibitors prevents the
implantation of endometrium to ectopic sites (Matsuzaki
et al., 2004a) and induces the regression of endometrial
explants in rats (Dogan et al., 2004) and mice (Ozawa et al.,
2006). However, the mechanisms underlying this regression
remain unclear.
To examine the potential application of celecoxib, a potent
COX-2 inhibitor, in the treatment of endometriosis, we inves-
tigated the effects of this drug on cell proliferation and apopto-
sis of cultured human endometrial epithelial cells (EECs). In
addition, our study evaluated the effect of celecoxib on in
vitro VEGF and PGE2 secretion, as well as on COX-2
expression in EECs from patients with endometriosis.
Materials and Methods
Subjects
A total of 45 patients who underwent diagnostic laparoscopy for infer-
tility participated in this study: 32 with untreated endometriosis
(Stages I and II) and 13 controls. Control subjects were infertile
women without endometriosis, with tubal factor infertility or unex-
plained infertility, undergoing diagnostic laparoscopy. Male factor
infertility was discarded. To avoid false negatives, only patients
who did not complain of pelvic pain were considered for the control
group. All patients were infertile, showed regular menstrual cycles
and had not received any hormonal medical treatment for the last
6 months. Staging of the disease was performed according to the
Revised American Society for Reproductive Medicine Classification
(ASRM, 1997). Further confirmation of the disease was performed
by histologic documentation. Biopsy specimens of eutopic endome-
trium were obtained from all subjects in the proliferative phase, as
described previously (Meresman et al., 2000). Our experience indi-
cates that there is a more efficient recovery of epithelial cells in the
proliferative phase than in the secretory phase of the cycle and other
authors have observed the same (Bongso et al., 1988). The biopsies
were taken from the anterior uterine wall toward the fundal area.
This study was approved by the Ethics and Research Committee of
the Biology and Experimental Medicine Institute of Buenos Aires,
Argentina, and all subjects included in the study signed informed
consents.
Isolation and culture of EECs
EECs were obtained from eutopic endometrial biopsies of endometrio-
sis patients and controls. The tissue was immediately placed into
culture medium and processed within 60 min of collection. Epithelial
cells were enzymatically separated and isolated by successive cen-
trifugation, and primary cultures were established for in vitro
studies using the method described previously (Meresman et al.,
2003a,b). Briefly, the explant was minced, washed and placed in
basic medium (Dulbecco’s modified Eagle’s medium F-12, Gibco,
Paisley, UK) containing 100 IU/ml penicillin, 100 mg/ml streptomy-
cin and 25 mg/ml amphotericin B (Gibco) with 0.5 mg/ml collagen-
ase (type I, Gibco). After a 2-h incubation at 378C in an atmosphere
of 5% CO2, the resulting suspension was centrifuged at 100  g for
5 min. The pellet containing glands was re-suspended in nutrient
medium and spun again at 100  g for 5 min. The final pellet
mainly contained epithelial cells. Any stromal cells remaining with
the glands were further separated by selective adherence to plastic
tissue culture dishes for 2 h. The enriched epithelial cells were cul-
tured with media enriched with 10% fetal bovine serum (FBS;
Gibco) and were grown to sub-confluence (70–80%) at 378C for
48 h before the experiments. In all cases, each biopsy was utilized
to run one or more experiments and there was no pooling of biopsies.
It has been previously shown that this method guarantees purity of
epithelial cells in culture (Meresman et al., 2003a,b). Briefly, after
48-h culture, EECs were fixed in 100% methanol for 20 min and
stained by indirect immunofluorescence using mouse monoclonal
anti-cytokeratin 56 kDa (reacts with cytokeratin polypeptides 1, 2,
5, 6, 7, 8, 11, 14, 16, 17, 18; Serotec Ltd, Oxford, UK) followed by
anti-immunoglobulin(Ig)-fluorescein isothiocyanate (Dako Ltd, Cam-
bridge, UK) as secondary antibody. Cultures incubated without the
primary antibody were included as controls in all experiments.
Slides were viewed on a microscope equipped with fluorescence and
differential interference contrast optics. Identical evaluation was
also done on endometrial stromal cells.
The broad-spectrum cytokeratin antibody produced clear labelling
in the epithelial cells. No staining of stromal cells was observed
with this anti-cytokeratin antibody and no fluorescent labelling was
observed in control cultures incubated with the secondary antibody
alone. The purity of culture was 85–90% for epithelial cells as deter-
mined by immunofluorescent staining.
Cell proliferation assay
Fifty thousand EECs per well were plated in 96-microwell plates and
incubated with 10% FBS medium. After a 48-h incubation, the cells
were washed and celecoxib (Pfizer, Caguas, USA) 10, 20, 25, 40,
50, 75 and 100 mM was added to supplemented 2.5% FBS medium.
The cells were incubated with the agent for 48 additional hours, at
which time the cells had reached 70% confluence. Vehicle control
cells consisted of EECs incubated with 2.5% FBS medium with 1 ml
dimethylsulphoxide (D5879, Sigma, St Louis, MO, USA) per ml of
medium, the vehicle in which celecoxib was reconstituted.
Twenty-four hours before harvesting, 1 mCi 3H-thymidine (Nen,
Dupont, Boston, MA, USA) was added to each microwell and DNA
synthesis was assessed by 3H-thymidine incorporation using a liquid
scintillation counter (Meresman et al., 2003a).
In order to determine whether added PGE2 could counteract the
growth inhibitory effect of celecoxib, EECs were treated with cele-
coxib (50 mM) and 200–2000 pg/ml PGE2 and incubated for 48 h
before determining 3H-thymidine incorporation, as mentioned
above. The dose of celecoxib used in this assay was chosen based
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on the lowest concentration that had a significant effect on inhibiting
cell proliferation.
Apoptosis assay
A total of 120 000 EECs per well were plated in Lab-Tek 8-well
culture chambers (Nalge Nunc, Naperville, IL, USA). After 48-h incu-
bation with 10% FBS medium, the cells were washed and cultured
with 2.5% FBS medium. Cells were incubated with the addition of cel-
ecoxib at 10, 20, 25, 40, 50, 75 and 100 mM or vehicle control. The
concentrations in the study were based on our titrations assessing
apoptosis with celecoxib for the EECs and from several published
studies on other cells (Jendrossek et al., 2003; Basu et al., 2005).
The cells were incubated for 24 additional hours and the percentage
of apoptotic cells was assessed by the Acridine Orange–Ethidium
Bromide (AO–EB) technique. AO is taken up by both viable and
non-viable cells and emits green fluorescence if intercalated into
double-stranded nucleic acid (DNA) or red fluorescence if bound to
single-stranded nucleic acid (RNA). EB is taken up only by non-viable
cells and emits red fluorescence by intercalation into DNA (Baskic
et al., 2006). It is specific for apoptotic forms of cell death and does
not significantly label cells undergoing necrotic death provoked by
injury (Abrams et al., 1993; Ribble et al., 2005). After addition of
the AO (4 mg/ml)–EB (4 mg/ml) mix, the cells were viewed using
a fluorescence microscope by two observers. There was no significant
difference in the results obtained between the two observers
(P ¼ 0.66).
Detection of COX-2 by immunocytochemistry
A total of 120 000 EECs per well were plated in Lab-Tek 8-well
culture chambers (Nalge Nunc). After a 48-h incubation with 10%
FBS medium, the cells were washed and incubated for an additional
24-h period with celecoxib at 25, 40, 50, 75 and 100 mM in medium
supplemented with 2.5% FBS or vehicle control. Following treat-
ments, chamber slides were fixed and standard procedures for
immunocytochemistry were performed. Cells were incubated over-
night with rabbit polyclonal anti-human COX-2 antibody (1:25,
sc-1747, Santa Cruz, Santa Cruz Biotechnology Inc., CA, USA) at
48C. After that, cells were treated for 60 min with the corresponding
biotinylated secondary antibody and later with streptavidine conju-
gated to horseradish peroxidase (LSABþSystem, Dako).
Binding was visualized by incubating slides with diaminobenzidine
and lightly counterstained with haematoxylin. As a negative control,
Ig of the same Ig class and concentration as the primary antibody
was used. The negative control showed absence of specific staining.
COX-2-positive cells were identified by the presence of brown cellular
reactivity.
Evaluation of COX-2 expression by western blot
A total of 106 EECs per well were plated in 6-well plates. After incu-
bation for 48 h with 10% FBS medium, the cells were washed and
incubated for an additional 24-h period with celecoxib at 25, 40, 50,
75 and 100 mM in medium supplemented with 2.5% FBS or vehicle
control. Following treatment, cells were lysed by scraping in chilled
lysis buffer supplemented with protease inhibitors (P8340, Sigma).
After freeze thawing, the lysate was centrifuged at 15 000  g for
10 min at 48C and protein concentrations in the supernatant were
measured by the Bradford assay (Bradford, 1976). Equal protein
samples (20 mg) were electrophoresed through a 10% sodium
dodecyl sulphate–polyacrylamide gel. The separated proteins were
transferred to nitrocellulose membranes, blocked for 1 h in 5%
low-fat powdered milk and incubated with the rabbit-polyclonal anti-
human COX-2 antibody (1:200, sc-1747, Santa Cruz) at 48C
overnight. After overnight incubation, membranes were incubated
with a goat peroxidase-conjugated anti-rabbit IgG secondary antibody
(1:1000, A4914, Sigma) at room temperature for 1 h. Protein bands
were visualized by incubating the membranes with an enhanced che-
miluminescence reagent (Perkin Elmer Life Science, Boston, MA,
USA) followed by exposure to Kodak X-Omat AR films. The levels
of protein were compared and analysed by densitometric studies
using Scion Image for Windows (Scion Corporation, Worman’s
Mill, CT, USA). Consistency of protein loading was validated with
b-actin loaded as control, using a mouse-monoclonal anti-human
b-actin antibody (1:2000, Abcam, Cambridge, UK) as primary anti-
body and an anti-mouse IgG as secondary antibody (1:1000,
HAF007, R&D Systems, Minneapolis, MN, USA).
Measurement of VEGF and PGE2 by ELISA
EEC cultures were left undisturbed at 378C for 48 h. Subsequently, the
cells were washed and incubated with basic medium supplemented
with 2.5% FBS for an additional 24 h after the addition of celecoxib
at 25, 50 and 100 mM or vehicle control. Cells were prepared for
assays as described above. The cell culture supernatant was
removed from each well and centrifuged for 5 min at 2000  g to
pellet any floating cells. Supernatants not assayed immediately were
frozen at 2808C. The conditioned medium was collected and
assayed for VEGF and PGE2 using commercial enzyme-linked immu-
nosorbent assay (ELISA) kits (Cytelisa, Human VEGF kit, EL-V,
Cytimmune Sciences Inc., MD, USA, and Correlate-EIA, PGE2
Enzyme Inmunoassay Kit, Assay Designs, Ann Arbor, MI, USA).
The sensitivity level for the VEGF ELISA was 26.6 pg/ml and for
the PGE2 ELISA was 13.4 pg/ml. The intra-assay variability for
VEGF and PGE2 was +7.3 and 8.9%, respectively, while the inter-
assay variability was +10.5 and 3.0% for VEGF and PGE2, respect-
ively. All samples were assessed in duplicate. Results were expressed
as percentage of vehicle control cells+SEM.
Statistics
Statistical comparisons were performed by Kruskal–Wallis non-
parametric analysis of variance test, followed by Dunn’s multiple
comparison test. Regardless of the statistical test, only a P-value
0.05 was considered significant.
Results
Effects of celecoxib on EEC proliferation
The effects of different concentrations of celecoxib on EEC
proliferation are displayed in Fig. 1. We found that in EEC cul-
tures from controls, celecoxib at low concentrations (10, 20, 25
and 40 mM) had no effect on basal DNA synthesis. In contrast,
after exposure to 50, 75 and 100 mM of celecoxib, the EECs
showed a significantly lower degree of cell proliferation
(P , 0.05, P , 0.01 and P , 0.001, respectively, versus
vehicle control cell proliferation).
In EEC cultures from endometriosis patients, 3H-thymidine
uptake was significantly down-regulated by celecoxib at high
concentrations: 50, 75 and 100 mM (P , 0.05, P , 0.01 and
P , 0.01, respectively, versus vehicle control cell prolifer-
ation). Lower concentrations of celecoxib (10, 20, 25 and
40 mM) had no significant effect on basal cell proliferation.
Effects of celecoxib on EEC apoptosis
The effects of different concentrations of celecoxib on EEC
apoptosis are displayed in Fig. 2. Celecoxib 50, 75 and
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100 mM showed a significant effect on endometrial growth,
enhancing apoptosis in endometrial cell cultures from controls
(P , 0.05, P , 0.001 and P , 0.001, respectively, versus
vehicle control apoptosis). In contrast, celecoxib 10, 20, 25
and 40 mM had no effect on basal apoptosis.
As well, in EECs from patients with endometriosis, cele-
coxib 50, 75 and 100 mM showed a significant effect enhancing
the apoptosis levels (P , 0.001, P , 0.001 and P , 0.01,
respectively, versus vehicle control apoptosis). In contrast,
celecoxib 10, 20, 25 and 40 mM had no significant effect on
basal apoptosis.
In this study and in previous works performed in our labora-
tory (Meresman et al., 2003a; Bilotas et al., 2007), we found no
significant differences in the degrees of cell proliferation and in
the percentage of apoptotic cells between endometrial cell cul-
tures from endometriosis patients and controls. Taking all these
results into account, we decided to utilize only cultures from
patients with endometriosis to evaluate the experiments that
follow.
Effect of celecoxib on COX-2 expression
The effect of different doses of celecoxib on the expression of
COX-2 in EECs in culture from patients with endometriosis
was studied by immunocytochemistry. COX-2 expression
was observed in the cytoplasm of EECs treated with celecoxib
(25 and 50 mM) as well as in vehicle control cells (Fig. 3A).
To assess whether there were variations in the level of
COX-2 protein after exposure to different doses of celecoxib
(25, 40, 50, 75 and 100 mM), COX-2 expression was analysed
by western blot. The pattern observed was similar to the one
seen by immunocytochemistry. COX-2 protein was observed
in celecoxib-treated EECs and in vehicle control cells,
showing a significant increase after treatment with 100 mM
of celecoxib (P , 0.05) (Fig. 3B).
Effect of celecoxib on PGE2 synthesis
COX-2 activity was evaluated by measuring the levels of PGE2
released into the conditioned media by EECs in culture treated
with different doses of celecoxib for 24 h. Fig. 4 shows that the
concentrations of celecoxib tested (25, 50 and 100 mM) signifi-
cantly reduced the levels of PGE2 in supernatants (P , 0.001
versus vehicle control).
Figure 1: Effects of celecoxib on cell proliferation in endometrial
cell cultures from control subjects and patients with endometriosis.
Endometrial epithelial cell cultures from control women (A) and
patients with endometriosis (B) treated with different doses of cele-
coxib or vehicle were assessed for cell proliferation by the
3H-thymidine uptake assay. Values+SEM are expressed as percen-
tage of vehicle control cell proliferation set as 100%. n ¼ 5 for
control women and n ¼ 5 for endometriosis patients. *P , 0.05,
**P , 0.01, ***P , 0.001 versus vehicle control.
Figure 2: Effects of celecoxib on apoptosis in endometrial cell cul-
tures from control subjects and patients with endometriosis. Endo-
metrial epithelial cell cultures from control women (A) and patients
with endometriosis (B) treated with different doses of celecoxib or
vehicle were assessed for apoptosis by the AO–EB technique.
Values+SEM are expressed as fold increase of vehicle control apop-
tosis set as 1. n ¼ 8 for control women and n ¼ 8 for endometriosis
patients. *P , 0.05, **P , 0.01, ***P , 0.001 versus vehicle
control.
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Effect of celecoxib on VEGF secretion
Fig. 5 shows the effect of celecoxib on the secretion of the
pro-angiogenic factor VEGF by EECs in culture treated with
different doses of celecoxib for 24 h. The concentrations of cel-
ecoxib tested (25, 50 and 100 mM) induced a significant
reduction in VEGF secretion compared with vehicle control
(P , 0.001, P , 0.05 and P , 0.001, respectively).
Effect of the addition of celecoxib and PGE2
on EEC proliferation
Since celecoxib caused growth inhibition and inhibited PGE2
secretion, we speculated that the addition of exogenous PGE2
to celecoxib-stimulated EECs in culture might abrogate the
effect of celecoxib on cell proliferation. Therefore, to deter-
mine whether celecoxib-induced growth inhibition could be
reversed by exogenous PGE2, EECs from patients with endo-
metriosis were stimulated simultaneously with 50 mM cele-
coxib and PGE2 in different doses. Growth inhibition
induced by 50 mM celecoxib could not be restored by addition
of exogenous PGE2 (P . 0.05 versus EECs stimulated with
celecoxib alone), thereby suggesting that celecoxib-induced
Figure 5: Effects of celecoxib on vascular endothelial growth factor
(VEGF) levels in endometrial cell cultures from patients with endome-
triosis. VEGF levels in conditioned media of endometrial epithelial
cells from patients with endometriosis treated with different concen-
trations of celecoxib or vehicle. Enzyme immunoassay was performed
in duplicate for each sample, bars represent media+SEM. Values are
expressed as percentage of vehicle control VEGF levels set as 100%.
n ¼ 13 *P , 0.05, ***P , 0.001 versus vehicle control VEGF levels.
Figure 3: (A) Immunocytochemistry of cyclooxygenase (COX)-2
expression in endometrial epithelial cell (EEC) cultures from subjects
with endometriosis after treatment with celecoxib. EECs from patients
with endometriosis were plated and incubated in cell chamber slides
with vehicle control conditions or with celecoxib 25 or 50 mM. In
negative control, normal rabbit IgG was used instead of primary anti-
body. Magnification: 400. (B) Effects of celecoxib on COX-2
expression in endometrial cell cultures from subjects with endometrio-
sis. Western blot analysis was performed on cell homogenates from
EEC cultures from patients with endometriosis after treatment with
25, 40, 50, 75 and 100 mM celecoxib or vehicle control. A representa-
tive blot is presented in the upper panel. The lower panel shows
quantification results for COX-2 expressed as a percentage of
vehicle control values+SEM. Consistency of protein loading was
validated with b-actin loaded as control. n ¼ 10 *P , 0.05 versus
vehicle control.
Figure 4: Effects of celecoxib on cyclooxygenase (COX)-2 activity
in endometrial cell cultures from patients with endometriosis.
COX-2 activity was studied measuring prostaglandin E2 (PGE2)
levels in conditioned media of endometrial epithelial cells from
patients with endometriosis treated with different concentrations of
celecoxib or vehicle. Enzyme immunoassay was performed in dupli-
cate for each sample, bars represent media+SEM. Values are
expressed as percentage of vehicle control PGE2 levels set as 100%.
n ¼ 9 ***P , 0.001 versus vehicle control PGE2 levels.
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growth inhibition in these cells may be independent of PGE2
levels. Results are displayed in Fig. 6.
Discussion
Current medical therapies for endometriosis, which are usually
aimed at reducing the endogenous steroid production, are not
effective in at least half of these patients, and their adverse
effect profiles constitute a significant problem (Rice, 2002;
Mihalyi et al., 2006). Given the inefficiency of the available
treatments, developing novel therapeutic strategies may be
useful to improve our ability to eliminate endometriotic
lesions and to prevent the recurrence of the disease.
In this study, epithelial cell cultures of eutopic human endo-
metrium from endometriosis patients were used in a model to
evaluate cell proliferation, apoptosis, COX-2 expression and
VEGF and PGE2 secretion in response to the addition of the
COX-2 inhibitor celecoxib. Although the cells employed in
this investigation were not derived from endometriotic
implants and their in vitro response may not be identical, the
rationale for the use of eutopic endometrial cells in short-term
culture as a model for endometriosis research has been docu-
mented previously (Surrey and Halme, 1990). Furthermore,
the epithelial fraction was the one studied since it has been
seen that COX-2 is preferentially expressed in this cell type
rather than in stromal cells (Ota et al., 2001).
Endometriosis is associated with increased COX-2 expres-
sion in eutopic and ectopic endometrium (Ota et al., 2001; Mat-
suzaki et al., 2004b). It has also been shown that PG levels are
elevated in serum and peritoneal fluid from endometriosis
patients (De Leon et al., 1986; Gazvani and Templeton,
2002). Inhibition of COX by conventional NSAIDs or selective
COX-2 inhibitors may therefore lead to relief of pain associ-
ated with endometriosis (Nasir and Bope, 2004).
Recently, multiple studies have suggested that the adminis-
tration of a COX-2 inhibitor reduces tumour development by
suppressing proliferation and angiogenesis as well as by
increasing apoptosis (Elder et al., 2000; Leahy et al., 2002;
Basu et al., 2005; Grosch et al., 2006). However, the effect
of COX-2 inhibitors on the endometrial cell growth in endome-
triosis is still unknown. The present study clearly demonstrates
that in EECs from patients with endometriosis and controls,
treatment with the selective COX-2 inhibitor, celecoxib, effec-
tively reduces cell proliferation and induces cell death. We
observed that celecoxib-induced apoptosis in EECs in culture
revealed by the AO–EB technique. Staining of apoptotic
cells with fluorescent dyes such as AO and EB is considered
a correct method for evaluating the changed nuclear mor-
phology. Recently, Baskic et al. compared several methods
for detecting apoptosis and necrosis in human leukocytes.
The authors conclude that both fluorescence methods, AO
and EB, provided reliable and reproducible results and distin-
guished clearly between subpopulations of apoptotic cells
(Baskic et al., 2006).
Celecoxib-induced apoptosis has previously been reported
by other authors. Basu et al. (2005) and Jendrossek et al.
(2003) described that treatment with celecoxib enhanced apop-
tosis in human breast cancer cells and Jurkat T cells, respect-
ively. There is evidence that the intrinsic pathway is
implicated in the activation of apoptosis after celecoxib treat-
ment (Jendrossek et al., 2003; Dandekar et al., 2005), yet
other authors have reported activation of the extrinsic
pathway (Kim et al., 2004; Liu et al., 2004). Furthermore,
the doses of celecoxib that significantly induced apoptosis in
the present study are clinically relevant since studies conducted
by other authors reveal that the concentration of COX-2 inhibi-
tors in serum of treated patients varies from 20 to 100 mM
(Munkarah et al., 2003; Basu et al., 2005). Nevertheless,
there are discrepancies in this regard. Other authors state that
the plasma concentration corresponds to 3 mM when patients
were treated with daily doses of 400 mg of celecoxib (Maier
et al., 2004; Grosch et al., 2006). According to these investi-
gators, the differences found in COX-2 inhibitor concentration
needed to observe anti-proliferative effects relies on the fact
that, in order to induce regression of tumour growth in patients,
several weeks of treatment are needed while, in vitro, the anti-
proliferative effects are seen in a few hours (Maier et al., 2005).
Our findings are consistent with previous results from other
authors who found that COX-2 inhibitors were successful at
inhibiting tumour growth in different cell lines (Wu et al.,
2004; Basu et al., 2005). Nevertheless, provision of exogenous
PGE2 did not reverse celecoxib-induced growth inhibition in
EECs. This suggests that celecoxib-induced growth inhibition
in EECs is independent of PGE2. Corroborating our findings
are previous reports that conclude that the addition of PGE2
had no effect on growth inhibition induced by COX-2 inhibi-
tors (Elder et al., 2000; Basu et al., 2005).
Additionally, celecoxib treatment reduces PGE2 secretion by
EECs from patients with endometriosis. PGE2 is the major PG
produced by EECs, and the production of secreted PGE2 is
therefore an appropriate measure of COX activity. A concen-
tration of 25 mM of celecoxib was effective at inhibiting
PGE2 secretion, however, under these conditions, growth inhi-
bition was not observed. The reduction of PGE2 production
induced by 25 mM celecoxib in EECs without the induction
of growth inhibition supports the proposal that the growth
Figure 6: Effects of PGE2 addition to celecoxib-stimulated endo-
metrial epithelial cell (EEC) cultures from endometriosis patients.
EEC cultures from patients with endometriosis treated with celecoxib
(50 mM) and different concentrations of PGE2 or vehicle were
assessed for cell proliferation by the 3H-thymidine uptake assay.
Values+SEM are expressed as percentage of vehicle control cell
proliferation set as 100%. n ¼ 9 ***P , 0.001 versus vehicle
control.
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arrest induced by higher concentrations (50–100 mM) of
celecoxib is not simply due to reduced PGE2 secretion. Similar
results were obtained by Grosch et al. (2001) and Han et al.
(2004) who speculated that the mechanisms involved in the
inhibition of cell proliferation due to celecoxib treatment are
independent of COX-2 activity and expression, since the con-
centrations needed to induce cell cycle arrest and inhibit pro-
liferation are higher than those needed to inhibit COX-2
activity. In agreement, it has been reported that celecoxib
induces apoptosis through mechanisms independent of
COX-2 in cancer cell lines (Jendrossek et al., 2003; Lai
et al., 2003; Grosch et al., 2006), and it can also induce apop-
tosis in cells deficient in COX-2 (Grosch et al., 2001; Pang
et al., 2007). Further studies are needed to confirm whether
the inhibitory effect triggered by celecoxib is independent of
COX-2 activity.
In addition to growth inhibition and COX-2 activity
reduction, we observed that COX-2 protein is significantly
increased in EECs from endometriosis patients treated with
100 mM celecoxib. Also, the western blot analysis for
COX-2 protein showed a clear but not statistically significant
increase after treatment with 25–75 mM celecoxib (Fig. 3B).
The mechanism for this is not known, however, it has been
suggested that COX-2-dependent products may inhibit
COX-2 expression in a negative feedback loop: here, celecoxib
treatment inhibited COX-2 activity, shown by reduced PGE2
secretion, perhaps resulting in removal of negative feedback
and COX-2 induction. There are similar data on COX-2 inhibi-
tor treatment leading to strong up-regulation of COX-2 protein
expression in several reports (Elder et al., 2000; Levitt et al.,
2004; Basu et al., 2005).
The establishment, maintenance and growth of endometrio-
sis are dependent in part on the development of new blood
vessels and it is known that the VEGF family is critical in
the process of angiogenesis. Activity of COX-2 results in an
increased VEGF expression (Li et al., 2002). In addition, it
has been shown that patients with endometriosis have a
greater concentration of VEGF in peritoneal fluid compared
with controls (Mahnke et al., 2000). Treating rats with rofe-
coxib induced a decrease in the explant size accompanied by
a decrease in peritoneal fluid VEGF levels (Dogan et al.,
2004). In our study, VEGF levels were significantly lower in
the celecoxib-treated EECs in comparison to vehicle control
cells. Down-regulation of eicosanoid production by COX-2
inhibitors is reported widely as a mechanism underlying their
antiangiogenic activity (Gately and Li, 2004).
To the best of our knowledge, this is the first in vitro study
suggesting a direct effect of celecoxib COX-2 inhibitor on the
reduction of endometrial growth. Nevertheless, in animal
models for endometriosis, it was shown that celecoxib prevented
the establishment of new endometriotic lesions and the growth of
already established ones (Matsuzaki et al., 2004a).
With the development of COX-2-specific inhibitors, better-
tolerated therapeutic options are available. In humans, only
one report has been published and suggested that the use of
COX-2-specific inhibitors was effective in the management
of pelvic pain associated with endometriosis (Cobellis et al.,
2004).
The role of COX-2 in endometrial growth inhibition
continues to be under investigation, and the data in our study
support further research on selective COX-2 inhibition as a
novel therapeutic modality in endometriosis.
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